Contact Information

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi, PhD

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Rachid Drissi

Research

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. Publications

                  Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.

                


                  Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.

                


                  Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.

                


                  Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.

                


                  Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.

                


                  Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

Biography

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

    “Curing Kids' Cancer through world-class Basic and Translational Research.”

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Awards, Honors & Organizations

Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016 Education and Research Scholarship, Moroccan Government, 1988 Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present Member, American Health Council, 2016 - Present Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020 Guest Editor, Journal of Nucleic Acids, 2013 - Present Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016 Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016 Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020 Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014 Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014 Member, Children’s Oncology Group (COG), 2009 - Present Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present Member, Cincinnati Cancer Consortium, 2009 - 2020 Member, American Association for Cancer Research, 2008 - Present Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

Education

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Professional Experience

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics2008 - 2020 Cincinnati Children’s Hospital Medical Center, Director, Brain Tumor Center Translational Research Laboratory, Division of Oncology Department of Pediatrics2008 - 2018 Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati College of Medicine, Assistant Professor, Division of Oncology, Department of Pediatrics2000 - 2007 St. Jude Children’s Research Hospital, Memphis, TN, Research Associate Investigator

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi, PhD

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Rachid Drissi

Research

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. Publications

                  Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.

                


                  Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.

                


                  Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.

                


                  Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.

                


                  Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.

                


                  Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

Biography

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

    “Curing Kids' Cancer through world-class Basic and Translational Research.”

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Awards, Honors & Organizations

Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016 Education and Research Scholarship, Moroccan Government, 1988 Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present Member, American Health Council, 2016 - Present Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020 Guest Editor, Journal of Nucleic Acids, 2013 - Present Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016 Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016 Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020 Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014 Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014 Member, Children’s Oncology Group (COG), 2009 - Present Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present Member, Cincinnati Cancer Consortium, 2009 - 2020 Member, American Association for Cancer Research, 2008 - Present Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

Education

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Professional Experience

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics2008 - 2020 Cincinnati Children’s Hospital Medical Center, Director, Brain Tumor Center Translational Research Laboratory, Division of Oncology Department of Pediatrics2008 - 2018 Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati College of Medicine, Assistant Professor, Division of Oncology, Department of Pediatrics2000 - 2007 St. Jude Children’s Research Hospital, Memphis, TN, Research Associate Investigator

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi, PhD

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Rachid Drissi

Contact Information

  • Call us at:
  • (614) 355-3749
  • Fax us at:
  • (614) 355-2927
  • Email Rachid Drissi, PhD
  • Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Rachid Drissi

Research

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. Publications

                  Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.

                


                  Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.

                


                  Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.

                


                  Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.

                


                  Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.

                


                  Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

Research

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. Publications

                  Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.

                


                  Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.

                


                  Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.

                


                  Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.

                


                  Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.

                


                  Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

Research

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. Publications

                  Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.

                


                  Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.

                


                  Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.

                


                  Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.

                


                  Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.

                


                  Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. Publications

                  Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.

                


                  Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.

                


                  Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.

                


                  Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.

                


                  Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.

                


                  Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms.

Interests

Pediatric Brain Tumors

Lab(s)

Center for Childhood Cancer

  • Pediatric Brain Tumors

  • Center for Childhood Cancer

                    Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.



                Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.



                Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.



                Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.



                Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.



                Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

View More Publications

  • Liao Y, Luo Z, Deng Y, Zhang F, Rao R, Wang J, Xu L, Kumar SS, Sengupta S, DeWire-Schottmiller M, Berry K, Garrett M, Fouladi M, Drissi R, Lu QR. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes. Neuro Oncol. 2021 Jul 1; 23: 1183-1196.
  • Zhu X, Lazow MA, Schafer A, Bartlett A, Senthil Kumar S, Mishra DK, Dexheimer P, DeWire M, Fuller C, Leach JL, Fouladi M, Drissi R. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. Acta Neuropathol Commun. 2021 Jan 11; 9: 14.
  • Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, Fuller C, Stevenson CB, DeWire M, Fouladi M, Drissi R. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol Cancer Res. 2020 Nov; 18: 1711-1723.
  • Sengupta S, Sobo M, Lee K, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul; 17: 1504-1514.
  • Kumar SS, Sengupta S, Lee K, Hura N, Fuller C, DeWire M, Stevenson CB, Fouladi M, Drissi R. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8; 8: 62962-62975.
  • Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2016 Sep; 129: 443-451.

Biography

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

Biography

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

Biography

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

Rachid Drissi, PhD, is a principal investigator in the Center for Childhood Cancer at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an associate professor of Pediatrics at The Ohio State University College of Medicine. Dr. Drissi focuses on understanding high-risk pediatric brain tumor biology and the mechanisms of synergy and resistance in these malignancies to identify molecular therapeutic targets and develop new treatment paradigms. He is the Director of the Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT). He provides support to the extensive translational research endeavors for the Brain Tumor Research Program. Dr. Drissi leads biology studies in multiple clinical trials through several consortia such as the Children’s Oncology Group, Pediatric Brain Tumor Consortium and CONNECT. Dr. Drissi received his master’s degree in Biochemistry and his doctorate degree in Molecular and Cellular Biology from the Pierre and Marie Curie University (Paris 6) in Paris, France. He then completed his postdoctoral fellowship at St. Jude Children’s Research Hospital, studying the effect of DNA damage on DNA replication in human cells and the regulation of telomerase by the oncogene c-Myc. As an associate investigator at St. Jude, Dr. Drissi focused on the relation between telomere dysfunction and the DNA damage signaling pathway. Later, as director of the Brain Tumor Center Translational Research Laboratory at Cincinnati Children’s Hospital Medical Center, Dr. Drissi’s research program expanded from a focus on the biology of telomeres and telomerase in cancer to a leadership role. His laboratory served as the core resource for designing and executing novel biomarkers and integrated proof of principle research studies in clinical trials developing new therapies for children and young adults with relapsed and high-risk brain tumors.

    “Curing Kids' Cancer through world-class Basic and Translational Research.”

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

  • Center for Childhood Cancer
  • Principal Investigator
  • Primary Department
  • Center for Childhood Cancer

Awards, Honors & Organizations

Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016 Education and Research Scholarship, Moroccan Government, 1988 Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present Member, American Health Council, 2016 - Present Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020 Guest Editor, Journal of Nucleic Acids, 2013 - Present Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016 Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016 Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020 Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014 Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014 Member, Children’s Oncology Group (COG), 2009 - Present Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present Member, Cincinnati Cancer Consortium, 2009 - 2020 Member, American Association for Cancer Research, 2008 - Present Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

Awards, Honors & Organizations

Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016 Education and Research Scholarship, Moroccan Government, 1988 Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present Member, American Health Council, 2016 - Present Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020 Guest Editor, Journal of Nucleic Acids, 2013 - Present Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016 Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016 Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020 Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014 Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014 Member, Children’s Oncology Group (COG), 2009 - Present Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present Member, Cincinnati Cancer Consortium, 2009 - 2020 Member, American Association for Cancer Research, 2008 - Present Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

Awards, Honors & Organizations

Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016 Education and Research Scholarship, Moroccan Government, 1988 Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present Member, American Health Council, 2016 - Present Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020 Guest Editor, Journal of Nucleic Acids, 2013 - Present Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016 Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016 Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020 Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014 Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014 Member, Children’s Oncology Group (COG), 2009 - Present Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present Member, Cincinnati Cancer Consortium, 2009 - 2020 Member, American Association for Cancer Research, 2008 - Present Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016 Education and Research Scholarship, Moroccan Government, 1988 Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present Member, American Health Council, 2016 - Present Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020 Guest Editor, Journal of Nucleic Acids, 2013 - Present Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016 Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016 Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020 Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014 Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014 Member, Children’s Oncology Group (COG), 2009 - Present Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present Member, Cincinnati Cancer Consortium, 2009 - 2020 Member, American Association for Cancer Research, 2008 - Present Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

  • Team Faculty Award, Cincinnati Children’s Hospital Medical Center, 2016
  • Education and Research Scholarship, Moroccan Government, 1988
  • Neural Tumors Research Forum seminar series (CME) co-organizer, Nationwide Children’s Hospital/Ohio State University, 2021 - Present
  • Director, Translational Research and Correlative Studies Laboratory for the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Nationwide Children’s Hospital/Ohio State University, 2021 - Present
  • Biology Chair and Co-PI, NCT03605550 clinical trial, 2018 - Present
  • Member of the Steering Committee, Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), 2017 - Present
  • Member, American Health Council, 2016 - Present
  • Editorial Board Member, International Journal of Radiology and Radiation Oncology, 2015 - Present
  • Member, Radiation Biology/Particle Therapy Research Group, Cincinnati Children’s Hospital Medical Center, OH, 2014 - 2020
  • Guest Editor, Journal of Nucleic Acids, 2013 - Present
  • Biology Chair, Pediatric Brain Tumor Consortium Study PBTC-036, 2013 - 2016
  • Member, Pediatric Brain Tumors Collaborative Research Group for the Ohio Neuro-Oncology Consortium, 2012 - Present
  • Member, Translational Committee of the Pediatric Brain Tumor Consortium (PBTC), 2012 - 2016
  • Member, Mentorship Advisory Committee, Cincinnati Children’s Hospital Medical Center, OH, 2012 - 2020
  • Member, Children’s Oncology Group (COG) Study Committee ADVL1112, 2011 - 2014
  • Member, Children’s Oncology Group (COG) Study Committee ADVL1321, 2011 - 2014
  • Member, Children’s Oncology Group (COG), 2009 - Present
  • Member, Cancer Therapy Evaluation Program (CTEP), 2009 - Present
  • Member, Cincinnati Cancer Consortium, 2009 - 2020
  • Member, American Association for Cancer Research, 2008 - Present
  • Member, COG high-grade glioma study (Biology co-investigator) ACNS0822, 2008 - Present
  • Neural Tumors Research Forum seminar series (CME) co-organizer, CCHMC, Brain Tumor Center, 2008 - 2020

Education

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Education

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Education

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Fellowship

St. Jude Children’s Research Hospital

Date Completed: 10/29/2000

Graduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 03/18/1994

Undergraduate School

University Pierre and Marie Curie, Paris VI, France

Date Completed: 06/30/1984

Undergraduate School

University of Rouen, France

Date Completed: 06/30/1983

Professional Experience

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics2008 - 2020 Cincinnati Children’s Hospital Medical Center, Director, Brain Tumor Center Translational Research Laboratory, Division of Oncology Department of Pediatrics2008 - 2018 Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati College of Medicine, Assistant Professor, Division of Oncology, Department of Pediatrics2000 - 2007 St. Jude Children’s Research Hospital, Memphis, TN, Research Associate Investigator

Professional Experience

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics2008 - 2020 Cincinnati Children’s Hospital Medical Center, Director, Brain Tumor Center Translational Research Laboratory, Division of Oncology Department of Pediatrics2008 - 2018 Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati College of Medicine, Assistant Professor, Division of Oncology, Department of Pediatrics2000 - 2007 St. Jude Children’s Research Hospital, Memphis, TN, Research Associate Investigator

Professional Experience

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics2008 - 2020 Cincinnati Children’s Hospital Medical Center, Director, Brain Tumor Center Translational Research Laboratory, Division of Oncology Department of Pediatrics2008 - 2018 Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati College of Medicine, Assistant Professor, Division of Oncology, Department of Pediatrics2000 - 2007 St. Jude Children’s Research Hospital, Memphis, TN, Research Associate Investigator

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics2008 - 2020 Cincinnati Children’s Hospital Medical Center, Director, Brain Tumor Center Translational Research Laboratory, Division of Oncology Department of Pediatrics2008 - 2018 Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati College of Medicine, Assistant Professor, Division of Oncology, Department of Pediatrics2000 - 2007 St. Jude Children’s Research Hospital, Memphis, TN, Research Associate Investigator

2018 - 2020 Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Associate Professor, Division of Oncology, Department of Pediatrics

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Center for Childhood Cancer

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-3749

Fax us at: (614) 355-2927

Email Rachid Drissi

                    700 Children's DriveColumbus, OH 43205 (map)
  • Call us at:
  • (614) 355-3749
  • Fax us at:
  • (614) 355-2927
  • Email Rachid Drissi
  • 700 Children’s DriveColumbus, OH 43205 (map)